A 2021 meta-analysis of 182 RCTs further confirmed the overall cardiovascular safety of DPP-4 inhibitors as a class, showing no significant association with major adverse cardiovascular events (MACEs), all-cause mortality, or HF risk (HR = 1.05; 95% CI, 0.96–1.15). Here, DPP4 is linked to hydrops fetalis.